ANGPT1, ANGPT2 and FGF2 have been linked in a US study to pathological complete responses to bevacizumab, the first approved recombinant humanized monoclonal antibody for breast cancer29, although most investigations into breast cancer genetic polymorphisms have focused on BRCA1/230,31. This evidence concerns the gene FGF2 and breast cancer.